New heart valve tested in japanese patients: a step forward for aortic stenosis treatment?

NCT ID NCT07193888

Recruiting now Disease control Sponsor: Abbott Medical Devices Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing the Navitor heart valve, a device used to replace a narrowed aortic valve without open-heart surgery. It will include 100 people in Japan with severe aortic stenosis. Researchers will check how many patients die within 30 days and whether the valve leaks after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Navitor Transcatheter Aortic Valve Implantation (TAVI) device
What this could lead to: If successful, this study could confirm that the Navitor valve works well and safely in everyday practice, supporting its use for treating severe aortic stenosis.
What could go wrong: This is a post-market study with only 100 participants, so results may not apply to all patients. Risks include death within 30 days or valve leakage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE AORTIC STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis cardiovascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE AORTIC STENOSIS

Contacts and locations

Locations

Kokura Memorial Hospital
RECRUITING

Fukuoka, Japan
Osaka Keisatsu Hospital
RECRUITING

Osaka, Japan
Shonan Kamakura General Hospital
RECRUITING

Kanagawa, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.